De:terminence

De:terminence is a precision medicine company specializing in functional oncology through the use of patient-derived organoids. Utilizing its proprietary Mini-Ring technology, the company performs high-throughput drug sensitivity screening on a patient's own tumor cells to identify the most effective therapeutic options. This approach aims to move beyond genomic sequencing by providing functional evidence of drug response in real-time. The company's platform is particularly focused on hard-to-treat and rare cancers, such as ovarian cancer and various solid tumors. By integrating live-cell imaging and automated analysis, De:terminence provides clinicians with data-driven insights to personalize cancer care.